How many drugs treat Duchenne muscular dystrophy?

Drug Landscape tracks 6 marketed treatments for Duchenne muscular dystrophy (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/duchenne-muscular-dystrophy.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Duchenne muscular dystrophy — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Duchenne muscular dystrophy (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Duchenne muscular dystrophy, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Amondys 45	CASIMERSEN	Sarepta	Antisense Oligonucleotide [EPC]	exon 53 of dystrophin pre-mRNA	2021-01-01
Viltepso	VILTOLARSEN	Nippon Shinyaku		exon 53 of dystrophin pre-mRNA	2020-01-01
Vyondys 53	GOLODIRSEN	Sarepta	Antisense Oligonucleotide [EPC]	exon 53 of dystrophin pre-mRNA	2019-01-01
Emflaza	DEFLAZACORT	Ptc Therap	Corticosteroid [EPC]		2017-01-01
Exondys 51	ETEPLIRSEN	Sarepta	Antisense Oligonucleotide [EPC]	exon 51 of dystrophin pre-mRNA	2016-01-01
Translarna	ATALUREN	PTC Therapeutics International Limited		Flavin reductase (NADPH)	2014-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Sarepta · 3 drugs in Duchenne muscular dystrophy
Nippon Shinyaku · 1 drug in Duchenne muscular dystrophy
PTC Therapeutics International Limited · 1 drug in Duchenne muscular dystrophy
Ptc Therap · 1 drug in Duchenne muscular dystrophy

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Duchenne muscular dystrophy:

Cite this brief

Drug Landscape (2026). Duchenne muscular dystrophy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/duchenne-muscular-dystrophy. Accessed 2026-06-10.

Duchenne muscular dystrophy full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing